SANDOZ SUNITINIB 50 MG
SUNITINIB : 50 MG · DIN 02532883 · SANDOZ CANADA INCORPORATED
Health Canada status: MARKETED
What is SANDOZ SUNITINIB?
SANDOZ SUNITINIB 50 MG contains SUNITINIB : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02532883, held by SANDOZ CANADA INCORPORATED, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 24-May-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SANDOZ SUNITINIB used for?
Treatment of gastrointestinal stromal tumour (GIST) after imatinib failure; metastatic renal cell carcinoma (MRCC); unresectable locally advanced or metastatic pancreatic neuroendocrine tumours.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02532883 |
|---|---|
| Brand name | SANDOZ SUNITINIB |
| Generic / active ingredient | SUNITINIB : 50 MG |
| Manufacturer | SANDOZ CANADA INCORPORATED |
| Strength | 50 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EX01 SUNITINIB |
| AHFS class | 68:20.06 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-May-2023 |
How is it administered?
Administered orally. Dosage and administration summary not fully detailed in provided text, but mentions 28-day cycles followed by 7-day dose-free periods in some contexts.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (Table of Contents lists section 11, but text ends before details).
How is it supplied?
Not explicitly detailed in the provided text (mentions strengths but not bottle/blister counts).
Contraindications
Hypersensitivity to sunitinib or any component of the formulation. Sandoz Sunitinib is contraindicated in pregnant women.
Warnings and precautions
Serious warnings: Tumour hemorrhage, LVEF decrease, hypertension, QT prolongation, cardiomyopathy, arterial thromboembolic events, TMA, hepatotoxicity, renal failure, and RPLS.
What can be used instead?
Other Canadian products sharing ATC code L01EX01 SUNITINIB. 18 of 26 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-SUNITINIB | 12.5 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02532190 |
| AURO-SUNITINIB | 25 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02532204 |
| AURO-SUNITINIB | 50 MG | CAPSULE | AURO PHARMA INC | MARKETED | DIN 02532220 |
| NAT-SUNITINIB | 12.5 MG | CAPSULE | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02552892 |
| NAT-SUNITINIB | 25 MG | CAPSULE | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02552906 |
| NAT-SUNITINIB | 50 MG | CAPSULE | NATCO PHARMA (CANADA) INC | MARKETED | DIN 02539284 |
| SANDOZ SUNITINIB | 12.5 MG | CAPSULE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02532840 |
| SANDOZ SUNITINIB | 25 MG | CAPSULE | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02532867 |
| SUTENT | 12.5 MG | CAPSULE | PFIZER CANADA ULC | MARKETED | DIN 02280795 |
| SUTENT | 25 MG | CAPSULE | PFIZER CANADA ULC | MARKETED | DIN 02280809 |
Who else supplies SUNITINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SUNITINIB appears in 2388 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.